Tagged with R

Saudi Arabia Saudi Arabia has long represented an alluring marketplace for the global MedTech industry. Not only does the Kingdom constitute the largest spender on healthcare across the Middle East and North Africa region, but its medical device sector has been experiencing consistent compound annual growth rates of over six percent and…

Saudi Arabia Eye health is vital to everyday life, yet it remains heavily underfunded compared to fields like cancer or diabetes. While global spending on oncology is set to reach USD 440 billion by 2028, ophthalmology will receive just USD 38 billion, according to IQVIA. This gap is striking given the growing…

Saudi Arabia With increased average disposable income in Saudi Arabia eliciting more sedentary lifestyles and less healthy dietary choices, more than 68 percent of all mortality in the Kingdom is nowadays attributed to non-communicable diseases (NCDs). Not only does this come at immense cost to the public purse, but also presents a…

Saudi Arabia When it was first initiated back in 2016, in the wake of the launch of Vision 2030, few industry insiders could have anticipated just quite how radical Saudi Arabia’s Health Sector Transformation Program (HSTP) would turn out to be. Since then, several significant milestones have been reached – the retreat…

Saudi Arabia Saudi Arabia’s pharmaceuticals market grew an impressive 9.1 percent in 2024 underscoring its position as the regional heavyweight, and projecting a sales value of around USD 11.6 billion, which constitutes approximately 32 percent of the total share of the Middle East and Africa (MENA) region in the global marketplace. Yet…

Puerto Rico Umberto Donato, president of DDD Group, a construction firm specialising in complex sectors including pharma, reflects on the company’s growth over the past decade and the role of infrastructure and facility design in attracting investment to Puerto Rico. He also discusses evolving client expectations, sustainability, the factors shaping the construction…

Global Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’ Pluvicto, RLT has proved its potential. But are current regulatory frameworks and healthcare systems prepared to integrate this less-than-typical therapy?…

Denmark With a mandate spanning pharmaceuticals, medical devices, and clinical research, the Danish Medicines Agency plays a central role in shaping both national health policy and European regulatory alignment. Under the leadership of Nils Falk Bjerregaard, the agency is navigating a period of accelerated transformation, defined by digitalisation, real-world evidence, decentralised…

Americas Diego Salas from the Latin American Federation of the Pharmaceutical Industry (FIFARMA) and Carlos Felipe Escobar Roa from the Instituto de Prospectiva e Innovacion en Salud (INNOS), writing in the May 2025 edition of DIA’s Global Forum magazine, discuss the findings of a pioneering report launched at the end of…

Investment In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent – they’re fighting for the soul, and pockets, of the industry’s future. We spoke to the CEOs of regional investment…

Switzerland Combining scientific rigour with entrepreneurial instinct, Igor Fisch charts a new path for gene and cell therapy manufacturing at NewBiologix. Focused on addressing the inefficiencies of current production models, the company develops stable platforms designed to lower costs, enhance quality, and expand patient access. With roots in the pioneering success…

Switzerland Daniela Marino, CEO and co-founder of CUTISS, leads a pioneering Swiss “tech-bio” company developing personalised skin grafts through advanced tissue engineering. With roots in academic research and over EUR 90 million raised, CUTISS has brought its lead product into Phase III trials, targeting burns and reconstructive surgery. Their unique approach…